Echinocandins: A promising new antifungal group

Indian Journal of Pharmacology

Volumn 36, Issue 2, 2004, Pages 65-71

  Randhawa, G K ^a,b   Sharma, G ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b NONE   (India)

Author keywords

Caspofungin; Fungal infections; Glucan synthase inhibitor

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450; DEXAMETHASONE; ECHINOCANDIN B DERIVATIVE; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MICAFUNGIN; MICONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NIKKOMYCIN; PHENYTOIN; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; EMBRYOTOXICITY; ESOPHAGITIS; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; FUNGAL STRAIN; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERSENSITIVITY REACTION; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG INFILTRATE; NAUSEA; NEPHROTOXICITY; NONHUMAN; OROPHARYNX; PEDIATRICS; PHLEBITIS; PNEUMONIA; PREGNANCY; SIDE EFFECT; TREATMENT FAILURE; UNITED STATES;

EID: 1942504871     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
2. Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, et al. Guidelines for the investigation of invasive fungal infections in hematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis 1997;16:424-36.
3. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990;17:10-3.
4. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001;14:685-91.
5. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients: A prospective, multicentre surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28: 1071-9.
6. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillous infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
7. Groll AH, Walsh TJ. Uncommon oppurtunistic fungi: New nosocomial threats. Clin Microbiol Infect 2001;7:8-24.
8. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001;10: 269-80.
9. Cailot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
10. Einsele H, Hebart H, Roller G, Loffler J, Rothenhofer I, Muller CA, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997;35:1353-60.
11. Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P, et al. Autopsy controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999;37: 3223-8.
12. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27A. NCCLS Wayne, PA; 1997.
13. NCCLS. Proposed reference method for broth dilution antifungal susceptibility testing of filamentous fungi. NCCLS document M28-P. NCCLS, Wayne, PA; 1998.
14. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46:3001-12.
15. Pound MW, Drew RH, Perfect JR. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 2002;15:183-94.
16. Perea S, Patterson TF. Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect 2002;17:99-105.
17. Abramowicz M, Zuccotti G, Rizack MA, Goodstein D, Faucard A, editors. The Medical Letter. Caspofungin (Cancidas) for Aspergillosis. 2001. Vol 43. p. 58-9.
18. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: An echinocandin antifungal agent. Clin Ther 2002;24:351-77.
19. Groll AH, Walsh TJ. Anti-fungal chemotherapy: Advances and perspectives. Swiss Med Wkly 2002;132:303-11.
20. Deresinski SC. Coccidioidomycosis: Efficacy of new agents and future prospects. Curr Opin Infect Dis 2001;14:693-6.
21. Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother 2003;37:90-8.
22. Denning DW. Echinocandins and Pneumocandins - a new anti fungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-4.
23. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997;35:79-86.
24. Morrison VA. The role of caspofungin and the echinocandins in the antifungal armamentarium. Curr Opin Investig Drugs 2002;3:1432-6.
25. Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991 and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997;41:1957-60.
26. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
27. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743, 872). Antimicrob Agents Chemother 1997;41:2339-44.
28. Leather H, Wingard J. Caspofungin - a viewpoint. Drugs 2001;61:1131.
29. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2070-2.
30. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25-30.
31. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002;31:183-7.
32. Laverdiere M, Restieri C, Habel F. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of E test and NCCLS reference methods. Int J Antimicrob Agents 2002;20:468-71.
33. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002;46:3634-6.
34. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida. spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002;43:13-7.
35. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743, 872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida. spp. Diagn Microbiol Infect Dis 1998;32:33-7.
36. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-5.
37. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
38. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9.
39. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001;45:327-30.
40. Chiou CG, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000;5:120-35.
41. De Pauw BE, Donnelly JP, Verweij PE, Meis JFGM. Current management of fungal infections in immunocompromised patients and polyene lipid complexes for treatment of invasive fungal infection. J Infect Dis Antimicrob Agents 1998;15:85-96.
42. Rubin MA, Carrol KC, Cahill BC. Caspofungin in combination with Itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002;34:1160-1.
43. Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002;46:2462-9.
44. van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 2002;46: 3394-400.
45. Nakai T, Uno J, Otomo K, Ikeda F, Tawara S, Goto T, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important moulds. Chemotherapy 2002;48:78-81.
46. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001;45:3322-7.
47. Wam PA, Sharp A, Morrissey G, Denning DW. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002;50:1071-4.
48. Arevalo MP, Carrillo-Munoz AJ, Salgado J, Cardenes D, Brio S, Quindos G, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: A comparative study with M27-A microdilution method. J Antimicrob Chemother 2003;51:163-6.
49. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001;7:11-6.
50. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303, 366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998;42:2726-30.
51. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998;42:873-8.